Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13462MR)

This product GTTS-WQ13462MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2&TNFRSF9 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001005862.3; NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 3604
UniProt ID P04626; Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13462MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2681MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ7278MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ7399MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ11901MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ4366MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ3664MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ9365MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ4888MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BYM338
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW